Episode Details
Back to Episodes
Mar 24, 2026 | ImmunityBio's Third FDA Warning Letter; Gilead Bets $1.68B on Ouro Medicines Autoimmune Bispecifi...
Published 3 months, 4 weeks ago
Description
ImmunityBio stock crashes 21%+ after FDA names CEO andchairman in third ANKTIVA promotional warning letter in seven months. Gilead acquires Ouro Medicines for $1.68B upfront to build autoimmune bispecific franchise. UCB commits $2B to first U.S. biologics plant in Georgia.
Visit us at: www.thepharmacloseout.com
pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, ImmunityBio, IBRX, ANKTIVA, FDA warning letter, Gilead, Ouro Medicines, gamgertamig, BCMA CD3, bispecific antibody, autoimmune disease, UCB, Bimzelx, biologics manufacturing, Shionogi, Apnimed, Milestone Pharmaceuticals, etripamil, CARDAMYST, Rezolute,Karyopharm, Xpovio, MFN drug pricing, Eli Lilly, Ocugen, Lilly